I am going to ASCO and will see if these guys have anything. I have analyzed their poster and think that they are missing few controls. It is important to have a good clinical protocol for a combination therapy. Their poster lacks AZD7762 plus a non-prodrug (same active) arm. I know this trick and will not fall for it neither the FDA when (and a big IF) they go forward to the human studies. I am expecting several great news at ASCO this year. AACR was light and ASCO should be heavy.
ASTX, ONXX, and I am not sure about CRIS and their data (via ROCHE). We have also several EU and AU approval waiting to happen.
"If they forward to the human studies" ? Dude they are currently in two phase three studies on humans. Their previous studies were on humans. If you think all of this is animal trials you really need to reread everything. You talk as if you you find the data poor or non-compelling which could, in theory, be the case if all the presented data came from monkeys and mice but it hasn't. In fact I can't remember there being animal studies (been in since 1.57). Really this is a safe treatment for some really awful cancers, that has, on occasion lead to complete responses. If I had cancer I'd want them to throw it in the mix.
In short: reread everything. And if you still want to claim that they may not be able to proceed to human trials then I would suggest leaving for a more appropriate field; like finger painting.